Navigation Links
Pharmasset Announces Clevudine and Hepatitis C Presentations at,EASL

rylation of PSI-6130 and inhibition of HCV NS5B.

About Clevudine

Clevudine is an oral, once-daily pyrimidine nucleoside analog that we are developing for the treatment of HBV. We licensed clevudine from Bukwang Pharm. Co., Ltd., a Korean pharmaceutical company. Bukwang has recently initiated the commercial launch of clevudine in the Korean market under the brand name Levovir. We plan to initiate two Phase 3 clinical trials of clevudine for registration in the United States and Europe in the second calendar quarter of 2007.

About R7128, a Prodrug of PSI-6130

R7128 is a polymerase inhibitor being developed for the treatment of chronic hepatitis C. R7128 is a prodrug of PSI-6130, a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase. The current R7128 Phase I clinical trial is a multiple center, observer-blinded, randomized and placebo- controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1.

About Hepatitis B Virus (HBV)

Hepatitis B viruses can cause liver disease leading to significant morbidity and death. HBV can cause either acute or chronic (lifelong) infection. The World Health Organization (WHO) has reported that approximately 350 million people worldwide have chronic HBV infection. According to the Centers for Disease Control and Prevention (CDC), approximately 1.25 million people in the United States are chronically infected with HBV, and the Hepatitis B Foundation reports that 100,000 people will become infected with HBV this year.

About Hepatitis C Virus (HCV)

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/24/2008)...Newswire/ -- There are a record 301,new medicines ... a new,report released here today during a briefin...tal illnesses have on patients, their families,an...ly 60 million American,adults. The briefing, led b... America (PhRMA), featured Emmy Award-winning acto...
(Date:7/24/2008)...to take body temperature, for home,and clinical us...-- Kidz-Med, Inc.,(subsidiary of American Scientif...s distributor of the Thermofocus(R) 5-in-1 non-con...ts of a clinical study,conducted by the Second Chi...n, Italy, which proves that the Thermofocus(R) mea...
(Date:7/23/2008)...c Therapy to Treat the Disease -, WAYNE, N.J. and.../ --,Bayer HealthCare Pharmaceuticals and Onyx Pha...that The New England Journal of Medicine published...avar(R) (sorafenib),tablets decreased the absolute...sectable hepatocellular carcinoma (HCC), or liver ...
(Date:7/23/2008)...ewswire/ -- The following was,released by the U.S....g Member Smith, and Members of the Committee.,Than...e I appeared before this Committee almost six mont...the talented and dedicated professionals,at the Ju...have come to,appreciate that much more deeply thei...
Breaking Medicine Technology:More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 1Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 2Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 3Canary Foundation and American Cancer Society Award Five Postdoctoral Fellowships in Early Cancer Detection 21694 4Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association 5965 1Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association 5965 2Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association 5965 3Abnormal Sleep Patterns in Older Men Spell Trouble 21692 1Abnormal Sleep Patterns in Older Men Spell Trouble 21692 2Defeat Diabetes Foundation Announces Martial Arts Defeat Diabetes 28R 29 Community Action Project 28TM 29 21690 1Defeat Diabetes Foundation Announces Martial Arts Defeat Diabetes 28R 29 Community Action Project 28TM 29 21690 2
... Maintained for at Least 24 Weeks, According,to Re...May 15, 2007 /PRNewswire/ -- Researchers from Guy,...icine have,announced the results from the first ra...valuating botulinum toxin type A (BTX-A,BOTOX(R))...ty (IDO),in patients with symptoms of overactive b...
...S WIRE)--May 17, 2007 - Pro-Pharmaceuticals,Inc. ...carbohydrate,compounds today announced that Elieze...Development and Manufacturing will present,"Pharm...umors of,5-FU with an Admixture of a Galactomannan...developmental Biology and Medicine,(ISOBM) Confere...
Other Medicine Technology:First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 2First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 3First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder 4Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 2Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 3Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 4Pro-Pharmaceuticals to Present Abstract at the International,Society of Oncodevelopmental Biology and Medicine Conference 5
(Date:7/25/2008)... PLEASANTON, Calif., July 25 /PRNewswire-FirstCa...ld leader in device-based mechanical,circulatory s...ing hearts,today announced that it will report it...st six months of fiscal 2008 on Thursday, July 31....uss its financial,results and operating activities...
(Date:7/25/2008)... Atlanta, GA July 24, 2008 Being overweight or o...,s health but is also a public health issue that i... journal Health Services Research reveals that t...elderly people could place a significant financial...illions of dollars across the entire current Medic...
(Date:7/25/2008)... DALLAS, July 25 /PRNewswire/ -- BeaconEquity.co...ocks making news today., Investors can view all o...ttp://BeaconEquity.com/m , Today,s Trade Alerts i...,MiddleBrook Pharmaceuticals Inc. (Nasdaq: MBRK ...aq: ADLR ), Affymetrix Inc. (Nasdaq: AFFX ) and,...
(Date:7/25/2008)...ataline is supporting the US Department of Defense...ion Golden Phoenix. Operation Golden Phoenix is a,...vent designed to assist, federal, state and local ... scenarios. Dataline is providing a vital, ad-ho...or medical use during the exercise., NORFOLK, Va....
Breaking Medicine News(10 mins):Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3
...rs have found that Vioxx painkiller manufactured b...heart attack within two weeks after patients start... patients out of 239 elderly patients suffered fro...first started taking Vioxx. The study results are ...
...itish Journal of Cancer, explained that the women ...reassurance that they are not necessarily on the b...elp women understand their test results and ease t...than 3500 women with slightly abnormal smears foun...
...he former commissioner of the Food and Drug Admini...tion following accusations of financial impropriet... that a grand jury had begun a criminal investigat...d to have told a federal magistrate, in a telephon...
... of a recruitment scam in the Health Department of...ous means to secure a job, were under the axe. // ... IV employees because they had apparently used fra...esorting to forgery and other nefarious means. It ...
Other Medicine News:Health News:Study Shows That Women Need To Be Explained About The Smear Test 2
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: